Relationship Between Specific Autoantibodies Against Platelet Glycoprotein(GPIIb/VIIIa and GPIbα) and Clinical Therapeutic Effect(glucocorticosteroid and IVIG) in Idiopathic Thrombocytopenic Purpura

Objective To evaluate the clinical significance of the relationship between specific autoantibodies against platelet glycoprotein(GPⅡb/Ⅲa and GPIbα) and clinical therapeutic effect(glucocorticosteroid and IVIG) in idiopathic thrombocytopenic purpura(ITP). To find the more economical, individualized treatment and the basis for the new clinical classification of ITP. Methods Specific autoantibodies against platelet glycoprotein were measured by a monoclonal antibody immobilization of platelet antigen assay(MAIPA). Results The frequency of catabatic cases in patients with mono-specific antibodies to GPⅡbⅡIa was significantly higher than that in patients with antibodies to both antigens(χ2=17.439,P0.01). No significant difference was observed between patients with antibodies to both antigens and patients who had mono-specific antibodies to GPIbα(χ2=0.995,P0.05). The clinical therapeutic effects(IVIG and glucocorticosteroid) in patients with mono-specific antibodies to GPⅡbⅡIa, antibodies to both antigens and no detectable antibody to either platelet antigen are not so different(P0.05). Conclusion The kinds of the specific autoantibodies against platelet glycoprotein might be related to clinical therapeutic effect in ITP. The autoantibodies would play a significant role in selecting effective treatment. Typing of autoantibodies for ITP is insufficient, the sample size should be expanded for further study.